Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

The Preclinical Proof of Concept Studies for Rare Diseases funding opportunity is offered by the National Institutes of Health through the National Center for Advancing Translational Sciences. This program is designed to address the significant unmet medical need associated with rare diseases, which individually affect small populations but collectively impact millions of people in the United States. Despite advances in disease understanding, very few rare diseases have effective treatments, largely due to limited funding and challenges in advancing early-stage therapeutic discoveries into later development. This opportunity seeks to bridge that gap by supporting preclinical studies that can demonstrate whether a therapeutic candidate is viable for further development. The primary objective of this grant is to fund efficacy studies in established preclinical models of rare diseases. Applicants are expected to generate data that demonstrates proof of concept for a therapeutic agent, which may include small molecules, biologics, or biotechnology-derived products. In addition to efficacy testing, applicants are encouraged to include pharmacodynamic and pharmacokinetic studies to better understand how the therapeutic behaves in biological systems. These combined measures are intended to provide a robust foundation for advancing candidates toward Investigational New Drug applications or clinical trials, particularly in cases of drug repurposing. Funding under this program is structured as an exploratory developmental grant with a maximum project period of two years. The combined direct costs may not exceed a specified cap over the project period, and annual limits are also enforced. The program does not require cost sharing, which lowers barriers for applicants. Funds may be used for activities directly related to preclinical efficacy testing, including acquisition of validated disease models, conducting experiments, and generating supporting pharmacological data. However, funding cannot be used for developing new disease models, and applicants must demonstrate access to validated models with sufficient availability. Eligibility for this opportunity is broad and inclusive, encompassing higher education institutions, nonprofits, for-profit organizations, and various levels of government entities within the United States. Foreign organizations are not eligible to apply directly, although certain foreign components may be allowed under specific conditions. Applicants must ensure compliance with all required registrations, including SAM, Grants.gov, and eRA Commons, prior to submission. Individual investigators must also meet credentialing requirements such as ORCID registration and alignment with institutional affiliations. The application process requires submission through approved electronic systems such as Grants.gov or NIH ASSIST. Applicants must follow detailed instructions outlined in the NIH application guide and include specific required components such as a Readiness of Agent attachment and a Partnership Plan. These components demonstrate the preparedness of the therapeutic candidate and the applicant’s strategy for collaboration with oversight committees and stakeholders. Applications that fail to include required materials or do not meet compliance standards will not be reviewed. Applications are evaluated through a rigorous peer review process focusing on scientific merit, innovation, feasibility, and the qualifications of the research team. Reviewers assess the significance of the research, the robustness of the experimental design, and the likelihood that the project will advance therapeutic development. Additional considerations include the appropriateness of the research model, the readiness of the therapeutic candidate, and the strength of collaboration plans. Only the most competitive applications proceed to advisory council review and potential funding decisions. The funding opportunity operates on a recurring annual cycle with defined submission deadlines. Applications must be submitted by early June each cycle, with subsequent review and award timelines extending into the following year. Applicants are encouraged to submit early to allow time for corrections. Key contacts are provided for scientific, peer review, and administrative inquiries, ensuring applicants have access to support throughout the process.

Emphasize strong biological rationale, validated disease models, and readiness of therapeutic candidate; ensure rigorous study design and clear path to IND development